Genmab — Marts 2015
-
Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous...
(www.prnewswire.com)
-
6,99 i USD/DKK..... Det kan altså mærkes hos genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind